Bicara Therapeutics Common StockNASDAQ: BCAX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$845.96 M
-32%vs. 3y high
72%vs. sector
-vs. 3y high
-vs. sector
-27%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$18.38-$0.94(-4.87%)

Dividend

No data over the past 3 years
$0.00-$17.48 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

BCAX Latest News

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
247wallst.com22 September 2024 Sentiment: POSITIVE

24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com16 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Bicara Therapeutics' shares began trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” All of the shares of common stock were sold by Bicara Therapeutics.

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
seekingalpha.com14 September 2024 Sentiment: POSITIVE

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.

What type of business is Bicara Therapeutics Common Stock?

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

What sector is Bicara Therapeutics Common Stock in?

Bicara Therapeutics Common Stock is in the Healthcare sector

What industry is Bicara Therapeutics Common Stock in?

Bicara Therapeutics Common Stock is in the Biotechnology industry

What country is Bicara Therapeutics Common Stock from?

Bicara Therapeutics Common Stock is headquartered in United States

What is Bicara Therapeutics Common Stock website?

https://www.bicara.com

Is Bicara Therapeutics Common Stock in the S&P 500?

No, Bicara Therapeutics Common Stock is not included in the S&P 500 index

Is Bicara Therapeutics Common Stock in the NASDAQ 100?

No, Bicara Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Bicara Therapeutics Common Stock in the Dow Jones?

No, Bicara Therapeutics Common Stock is not included in the Dow Jones index

When was Bicara Therapeutics Common Stock the previous earnings report?

No data

When does Bicara Therapeutics Common Stock earnings report?

The next expected earnings date for Bicara Therapeutics Common Stock is 28 February 2025